BOSTON and ROLLE, Switzerland - SOPHiA GENETICS (NASDAQ: SOPH), a leader in data-driven medicine, has announced a partnership with Karkinos Healthcare to enhance cancer research and care in India. This collaboration aims to provide advanced genomic solutions and improve personalized treatment for blood cancers and solid tumors, particularly in rural and underserved communities.
Karkinos Healthcare, an oncology platform focused on early detection, diagnostics, and treatment, is set to adopt the SOPHiA DDM™ Platform. This technology is expected to bolster their capabilities in addressing the accessibility and affordability gaps in cancer care through their 'Community as a Cancer Centre' initiative.
Dr. Jurgi Camblong, CEO and Co-founder of SOPHiA GENETICS, emphasized the shared goal with Karkinos to expand access to precision oncology and equip local health institutions with necessary tools for data-driven medicine. The SOPHiA DDM™ Platform will enable Karkinos Healthcare to advance research and streamline workflow for various cancers, including Myeloid and Lymphoma, as well as solid tumors like ovarian, prostate, and breast cancers.
Dr. R Venkataramanan, Founder and CEO of Karkinos Healthcare, highlighted the partnership's potential to generate world-class research for faster and more accurate cancer diagnosis and management, with a focus on precision medicine for the underprivileged in India.
The SOPHiA DDM™ Platform offers tailored next-generation sequencing (NGS) workflows to accelerate analysis from sample to report, facilitating rapid, high-quality data acquisition for clinical research studies.
This strategic alliance is part of SOPHiA GENETICS' broader mission to make data-driven medicine a standard of care globally. The company's technology is already in use by a wide network of hospitals, laboratories, and biopharma institutions around the world.
Karkinos Healthcare, supported by prominent investors including the Tata Group and Reliance Industries, operates with a vision to provide comprehensive cancer care closer to patients' homes, leveraging a distributed cancer care network and partnerships with leading healthcare institutions.
This press release statement indicates the forward-looking nature of the partnership, with the caveat that actual results may differ from expectations due to various factors.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.